Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results

     Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results

Webcast and Conference Call Today at 5:00 p.m. Eastern Time

PR Newswire

JERSEY CITY, N.J., Nov. 1, 2012

JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today announced the Company's financial results for the quarter
ended September 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Third Quarter 2012 Financial Highlights:

  oDIFICID® gross sales in the U.S. and Canada of $18.7 million and net sales
    of $16.0 million, represent increases of 3.9% and 4.9% over the second
    quarter, respectively
  oEstimated DIFICID ex-wholesaler and ex-specialty pharmacy treatments
    shipped in the third quarter to U.S. and Canadian purchasing customers,
    including hospitals, retail pharmacies and long-term care facilities,
    increased by approximately 7.2% compared to the second quarter
  oContract revenues from collaborations, which include royalties and bulk
    pharmaceutical sales, were $1.9 million
  oTotal revenues were $17.9 million
  oCash, cash equivalents and short-term investments at September 30 totaled
    $98.2 million
  oNet loss for the third quarter was $26.8 million, or $0.56 per share

Financial Overview
Total revenues for the three months ended September 30, 2012 and 2011 were
$17.9 million and $11.1 million, respectively, an increase of $6.8 million.
In the three months ended September 30, 2012, we recognized $16.0 million of
net product sales of DIFICID in the U.S. and Canada. We recognize product
sales of DIFICID upon delivery of product to our wholesalers and specialty
pharmacies. In addition, we recognized $1.9 million in contract revenue under
our collaborations with Astellas Pharmaceuticals Europe Ltd., Astellas Pharma,
Inc. and Specialized Therapeutics Australia, Pty. Ltd.

We reported a net loss for the third quarter of 2012 of $26.8 million, or
$0.56 per share on both a basic and diluted basis, as compared to a net loss
for the third quarter 2011 of $26.4 million, or $0.57 per share on both a
basic and diluted basis.

Research and development expense for the three months ended September 30, 2012
and 2011 was $10.7 million and $10.4 million, respectively, an increase of
$0.3 million.

Selling, general and administrative expense for the three months ended
September 30, 2012 and 2011 was $26.4 million and $24.0 million, respectively,
an increase of $2.4 million. The increase was due to higher salary expense and
increased legal and other consulting services.

Co-promotion expenses with Cubist for the three months ended September 30,
2012 and 2011 were $4.4 million and $2.9 million, respectively, an increase of
$1.4 million. The increase represented certain profit-sharing expenses earned
by Cubist under our April 2011 DIFICID co-promotion agreement.

As ofSeptember 30, 2012, we held cash, cash equivalents and short-term
investments of$98.2 million. This does not include proceeds from an
agreement announced October 8, 2012 to sell our stake in Optimer
Biotechnology, Inc. (OBI). The sale is expected to result in net proceeds of
$59.8 million and was structured to close in two tranches. The first closing
took place on October 19, 2012 and the second closing is expected to take
place in the first quarter of 2013.

We had 47.7 million shares outstanding on September 30, 2012.

DIFICID Update
"Over the last two quarters, we have expanded global availability of
fidaxomicin through the launch of DIFICLIR in Europe with our partner Astellas
Pharma Europe,our own launch of DIFICID in Canada and the continued
negotiation of new agreements," continued Mr. Lichtinger. "As part of our
life-cycle management strategy, we are pursuing new indications to expand the
utility of DIFICID for patients in need. This morning, we announced the dosing
of the first patient in our Phase 3b clinical trial evaluating DIFICID as a
prophylactic in patients undergoing hematopoietic stem cell transplant, a
population with a high prevalence of CDAD and without any FDA-approved
preventative treatments for the disease."

DIFICID net sales of $16.0 million in the third quarter of 2012 reflected a
4.9% increase over the second quarter of 2012 and a 51.5% increase over the
prior year period.

Gross sales to U.S. and Canadian wholesalers and specialty pharmacies of $18.7
million in the third quarter of 2012 represented 6,692 treatments shipped, and
a 3.9% increase over the $18.0 million in gross sales for the second quarter
of 2012 and a 53.7% increase from the prior-year period. Further,
approximately 6,600 DIFICID treatments were shipped from wholesalers and
specialty pharmacies to U.S. and Canadian purchasing customers, including
hospitals, retail pharmacies and long-term care facilities, in the third
quarter, a 7.2% increase over the prior quarter and an increase of 131.7% over
the prior year period.

Additionally, as of September 30, 2012:

  oInventory levels at wholesalers remain within the range of 14 to 28 days
    of demand
  oApproximately 2,360 U.S. hospitals had ordered DIFICID
  oApproximately 79% of U.S. hospitals covered by Optimer have reordered
    DIFICID
  oThe number of target hospitals including DIFICID on their formularies was
    approximately 960
  oApproximately 95% of all commercial lives and 80% of Medicare Part D lives
    in the United States had formulary payor access to DIFICID, bringing the
    total percent of insured patients with covered access to 88%.

DIFICID Strategic Update
"In October we launched new initiatives to educate the hospital market about
our recently-instituted discount program and on DIFICID RxAssist, and we are
optimistic that these efforts will help facilitate patient access to DIFICID
while in the hospital and upon discharge. We have received positive initial
feedback from hospitals to our initiatives since their introduction last
month," said Pedro Lichtinger, President and CEO of Optimer. "Separately, we
also are engaging in efforts to educate customers about the NTAP program,
which can provide an additional reimbursement to eligible hospitals for
qualifying Medicare Part A in-patient cases where DIFICID is utilized. And,
in addition to our strategic initiatives, we continue educational efforts to
provide information to customers on the burden of CDI, providing data that
help address gaps in evidence regarding readmissions and disease burden."

Conference Call and Webcast
Optimer will host a conference call and webcast to discuss its third quarter
financial results and to provide a corporate update today at5:00 p.m. Eastern
time (2:00 p.m. Pacific time).

The conference call may be accessed by dialing (877) 280-7280 for domestic
callers and +1 (678) 825-8232 for international callers. Please specify to the
operator that you would like to join "Optimer's Financial Results Call." The
conference call will be webcast live under the Investors section of Optimer's
website atwww.optimerpharma.com, where it and any accompanying slides will be
archived for 30 days following the call. 

AboutClostridium difficile-associated Diarrhea (CDAD)
Clostridium difficileinfection (CDI) is a serious illness resulting from
infection of the inner lining of the colon byC. difficilebacteria, which
produce toxins that cause inflammation of the colon, severe diarrhea and, in
the most serious cases, death.Clostridium difficile-associated diarrhea is
the most common symptom of CDI. In recent years,C. difficilehas surpassed
methicillin-resistantStaphylococcus aureus(MRSA) as the leading cause of
healthcare-acquired infections in community hospitals. Patients typically
develop CDAD from the use of broad-spectrum antibiotics that disrupt normal
gastrointestinal (gut) flora, possibly allowingC. difficilebacteria to
flourish.

About DIFICID® (fidaxomicin) Tablets
DIFICID is the first macrolide antibacterial drug indicated forClostridium
difficile-associated diarrhea (CDAD) to be approved in over 25 years in the
U.S. It is indicated for the treatment of CDAD in adults 18 years of age or
older. DIFICID is administered in 200 mg tablets given orally twice daily.

Important Safety Information for DIFICID
DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or
to any of the excipients in the formulation. DIFICID should not be used for
systemic infections. Only use DIFICID for infection proven or strongly
suspected to be caused byC. difficile. Prescribing DIFICID in the absence of
a proven or strongly suspectedC. difficileinfection is unlikely to provide
benefit to the patient and increases the risk of the development of drug
resistant bacteria. The most common adverse reactions are nausea (11%),
vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia
(2%) and neutropenia (2%).

Please visitwww.DIFICID.comor call 855-DIFICID (343-4243) for full
prescribing information for DIFICID.

AboutOptimer Pharmaceuticals
Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, anFDA-approved macrolide antibacterial drug for the treatment
ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in theEuropean
Unionwhere its partner,Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™. The Company is exploring
marketing authorization in other parts of the world whereC. difficilehas
emerged as a serious health problem, includingAsia. Additional information
can be found at http://www.optimerpharma.com.

Forward-Looking Statements
Statements included in this press release that are not a description of
historical facts are forward-looking statements, including without limitation
statements related to Optimer's initiatives to increase patient access to
DIFICID, the timing of the second closing of Optimer's sale of its remaining
equity in OBI, Optimer's pursuit of new indications for DIFICID and Optimer's
on-going educations efforts regarding its patient access initiatives and the
burden of CDI. Words such as "believes", "would", "anticipates", "plans",
"expects", "may", "intend", "will", and similar expressions are intended to
identify forward-looking statements. The inclusion of forward-looking
statements should not be regarded as a representation by Optimer that any of
its plans will be achieved. These forward-looking statements are based on
management's expectations on the date of this releaseand Optimer undertakes
no obligation to update or revise these statements, except as may be required
by law. Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Optimer's
businessincluding, without limitation, risks relating to:Optimer'sability
to continue driving adoption and use of DIFICID, DIFICID's ability to compete
with cheaper generic alternatives, whether healthcare professionals will
prescribe DIFICID,the extent to which DIFICID will be accepted on additional
hospital formularies and the timing of hospital formulary decisions, whether
Optimer's patient access initiatives will result in additional DIFICID
prescriptions in the hospital or retail markets, whether Rx Assist is utilized
and whether it will facilitate access to DIFICID, whether and when the closing
conditions applicable to the second closing of Optimer's sale of OBI equity
will be satisfied, and other risks detailed inOptimer'sfilings with
theSecurities and Exchange Commission.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005

OPTIMER and DIFICID are trademarks ofOptimer Pharmaceuticals, Inc.All other
trademarks are the property of their respective owners.

Optimer Pharmaceuticals, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
                      Three Months Ended          Nine Months Ended
                      September 30,               September 30,
                      2012           2011           2012           2011
Revenues:
Product sales, net   $            $            $            $
                      15,983,575    10,551,820    45,596,203     10,551,820
Contract revenue     1,891,959      -              36,417,444     69,165,000
Other                -              500,264        2,106          645,197
 Total revenues    17,875,534     11,052,084     82,015,753     80,362,017
Cost and expenses:
Cost of product      1,421,267      615,955        5,974,858      615,955
sales
Cost of contract     1,213,473      -              2,957,655      4,273,532
revenue
Research and         10,710,251     10,405,459     33,335,435     29,074,229
development
Selling, general and 26,444,831     24,015,928     80,824,042     50,582,925
administrative
Co-promotion         4,357,463      2,928,760      19,440,629     2,928,760
expenses with Cubist
Total operating      44,147,285     37,966,102     142,532,619    87,475,401
expenses
Loss from operations  (26,271,751)   (26,914,018)   (60,516,866)   (7,113,384)
Gain on
de-consolidation of   -              -              23,782,229     -
OBI
Equity in net loss of (694,433)      -              (1,849,254)    -
OBI
Interest income and   195,504        108,431        316,209        227,533
other, net
Consolidated net      (26,770,680)   (26,805,587)   (38,267,682)   (6,885,851)
loss
Net loss attributable
to non-controlling    -              378,916        280,344        1,353,204
interest
Net loss attributable $             $             $             $ 
to Optimer            (26,770,680)  (26,426,671)  (37,987,338)   (5,532,647)
Pharmaceuticals, Inc.
Net loss per share -  $        $        $        $     
basic and diluted      (0.56)        (0.57)       (0.80)        (0.12)
Weighted average
number of shares used
to compute net
 loss per share -   47,619,006     46,624,390     47,252,123     45,269,621
basic and diluted
Comprehensive loss    $            $             $             $ 
                      (27,353,113)   (27,976,402)  (37,437,798)   (7,533,274)

Optimer Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
                                September 30,           December 31,
                                2012                    2011
                                (unaudited)
ASSETS
Current assets:
 Cash and cash equivalents  $      86,872,487  $      31,787,512
  Short-term investments     11,339,862              78,791,066
 Trade accounts receivable,  6,240,170               6,563,645
net
 Accounts receivable, other  1,675,091               52,289,290
 Inventory                   13,279,904              3,947,380
 Prepaid expenses and other 1,761,757               3,781,830
current assets
Total current assets            121,169,271             177,160,723
Equity investment in OBI        28,319,359              -
Property, equipment and other,  3,990,520               2,590,715
net
Long-term investments           882,000                 882,000
Other assets                    1,420,841               1,389,734
Total assets                    $     155,781,991   $     182,023,172
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities:
 Accounts payable            $                 $      
                                9,601,742               9,860,462
 Accrued expenses            19,447,265              21,447,544
 Deferred revenue            154,416                 -
Total current liabilities       29,203,423              31,308,006
Deferred rent                   227,337                 151,141
Stockholders' equity           126,351,231             150,564,025
Total liabilities and           $     155,781,991   $     182,023,172
stockholders' equity



SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com